// App-Quantinova.ai

BSH2020‐EP‐068 : Implementing venetoclax treatment into day case setting for patients at high risk of tumour lysis syndrome; University Hospital Southampton NHS Foundation Trust experience

Researchers

Presenter

  • K. Matulay

Principal Investigators

  • F. Forconi

  • A. Duncombe

  • H. Launders

  • A. Kostourou Korovesi

  • D. Labay

Medical Centers

  • Haematology, Southampton University Hospital NHS Foundation Trust, Southampton, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Cancer antigen 15-3

  • Creatinine

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved